Combination therapy of TIGIT mAb tiragolumab and PD-L1 mAb atezolizumab has been reported to enhance overall response rate in the context of metastatic NSCLC with PD-L1 positive expression [115]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.